BDENZA 40MG CAPSULES
| Parameter | Details |
|---|---|
| Product Name | Bdenza Capsules |
| Strength | 40 mg |
| Active Ingredient | Enzalutamide |
| Drug Class | Androgen Receptor Inhibitor |
| Dosage Form | Capsule |
| Route of Administration | Oral |
| Packaging | Bottle/Strip (as per manufacturer) |
| Storage Condition | Store below 30°C in a dry place |
| Prescription Required | Yes |
| Usage | Treatment of prostate cancer |
BDENZA 40MG CAPSULES
Bdenza 40mg Capsules contains Enzalutamide, a prescription androgen receptor inhibitor used for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and other advanced prostate cancer conditions. By blocking androgen receptor signaling pathways, Bdenza helps slow cancer cell growth and disease progression under specialist supervision.
Bdenza works by preventing androgens from stimulating prostate cancer cells, thereby reducing tumor proliferation and spread. This targeted hormonal therapy plays an important role in managing advanced prostate cancer, particularly in patients who have progressed despite prior hormonal treatments.
Administered orally, the Bdenza 40mg Capsule offers the convenience of outpatient cancer therapy while maintaining clinical effectiveness. It is prescribed as part of long-term prostate cancer management plans and should be taken strictly as directed by an oncologist or urologist to ensure optimal treatment outcomes and patient safety.
Product Features
- Targeted prostate cancer therapy capsule
- Contains Enzalutamide 40 mg
- Used in advanced and metastatic prostate cancer
- Androgen receptor signaling inhibitor
- Oral capsule dosage form
- Suitable for long-term cancer therapy
- Manufactured under strict pharmaceutical quality standards
- Prescription-required oncology medicine
How It Helps
- Blocks androgen receptor signaling to slow prostate cancer growth
- Helps control the progression of advanced and metastatic prostate cancer
- Reduces the stimulation of cancer cells by male hormones
- Supports effective long-term prostate cancer management
Reviews
There are no reviews yet.